TSE

Over 40% of Businesses Experience Revenue Losses from Technology Downtime, Cloud Complexity, and Legacy System Constraints

Retrieved on: 
Tuesday, October 24, 2023
TCO, IT as a service, Ageing, Strategic partnership, Rights, Organization, Data management, TSE, Adaptability, Retail, Growth

SANTA CLARA, Calif., Oct. 24, 2023 /PRNewswire/ -- Fifty-five percent of enterprises are struggling to derive meaningful insights from their data, highlighting an industry-wide need to deliver technology faster, more reliably and in more places, according to a recent survey by Hitachi Vantara, the modern infrastructure, data management and digital solutions subsidiary of Hitachi, Ltd. (TSE: 6501). The survey revealed ongoing challenges related to security, inflexible systems, isolated data, a skilled labor shortage, and the need for infrastructure agility. These challenges are heightened by rising data complexities, rigid technology environments, and increasing costs due to aging or legacy infrastructure.

Key Points: 
  • These challenges are heightened by rising data complexities, rigid technology environments, and increasing costs due to aging or legacy infrastructure.
  • The survey exposed major legacy infrastructure challenges causing IT decision-makers to report negative impacts on their businesses.
  • Key findings include:
    56% of businesses reported a significant impact on revenue due to technology downtime.
  • It enables enterprises to innovate, collaborate, and flourish amid ever-evolving technology," said Gary Lyng, vice president, product and solutions, Hitachi Vantara.

Advantest Issues Call for Papers for VOICE 2024 Developer Conference in San Diego, California

Retrieved on: 
Wednesday, October 18, 2023
Linda, Internet of things, Digital, WLR, Intelligence, WiGig, RF, ICS, History, HPC, MIMO, Conference, VOICE, Advantest, Artificial intelligence, City, OSAT, OEE, TSE, Abstract, IDMS, Radio frequency, Cost, Hot Topic, SIP, Video game, Mobile phone, Instrumentation, Consumer electronics

TOKYO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) today announced a global call for papers for its VOICE 2024 Developer Conference focusing on leading-edge technologies and future trends.

Key Points: 
  • TOKYO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) today announced a global call for papers for its VOICE 2024 Developer Conference focusing on leading-edge technologies and future trends.
  • The conference will be held in San Diego, California, on June 3-5, 2024.
  • Attendees at the conference sessions in June 2024 will vote for the best papers via the VOICE mobile app, with winning presenters receiving prizes and awards during the closing ceremonies.
  • For more information about the VOICE 2024 Developer Conference or sponsorship opportunities, visit https://voice.advantest.com/ or email [email protected] .

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

Retrieved on: 
Monday, October 23, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, DXD, AstraZeneca, Progression-free survival, IHC, HER2, Congress, PFS, European Society for Medical Oncology, HIV disease progression rates, ADC, Daiichi Sankyo, Risk, TSE, Breast cancer, Patient, Death, Medical imaging

Median PFS was 6.9 months in patients treated with datopotamab deruxtecan compared to 4.9 months in those treated with chemotherapy.

Key Points: 
  • Median PFS was 6.9 months in patients treated with datopotamab deruxtecan compared to 4.9 months in those treated with chemotherapy.
  • Results also showed a confirmed objective response rate (ORR) of 36.4% in patients treated with datopotamab deruxtecan compared to an ORR of 22.9% in patients treated with chemotherapy.
  • In the datopotamab deruxtecan arm, the all-grade interstitial lung disease (ILD) rate was low (3%) and the majority of events were low grade.
  • At the July 17, 2023 data cut-off, 93 patients remained on treatment with datopotamab deruxtecan and 39 remained on chemotherapy.

ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer

Retrieved on: 
Monday, October 23, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, CR, Female, Neoplasm, ERBB2, Lymphocytopenia, NSCLC, AstraZeneca, Journal of Thoracic Oncology, DOR, Thrombocytopenia, Vomiting, Hypokalemia, HER2, Diarrhea, Lung cancer, News, Nausea, Pneumonia, Transaminase, Lung, ADC, Disease, Daiichi Sankyo, TSE, Immunotherapy, ORR, Anemia, Leukopenia, Safety, European, Patient, Diagnosis, Neutropenia, Mutation, Fatigue, Pharmaceutical industry, Medical imaging, MD, EU

ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Key Points: 
  • ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • In DESTINY-Lung02, ENHERTU (5.4 mg/kg) demonstrated a confirmed objective response rate (ORR) of 49.0% (95% confidence interval [CI]: 39.0-59.1) in patients with previously treated advanced or metastatic HER2 mutant NSCLC as assessed by blinded independent central review (BICR).
  • Grade 5 adverse reactions occurred in 1.4% of patients, including interstitial lung disease (1.0%).
  • Following approval in the EU, an amount of $75 million is due from AstraZeneca to Daiichi Sankyo as a milestone payment in HER2 mutant non-small cell lung cancer.

Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Retrieved on: 
Monday, October 23, 2023
General Health, Health, Pharmaceutical, Clinical Trials, Oncology, Neoplasm, DXD, EGFR, Arm, PD-L1, NSCLC, AstraZeneca, Incidence, ESMO, Progression-free survival, Trae tha Truth, Fatigue, Stomatitis, Congress, European Society for Medical Oncology, PFS, MD, Docetaxel, CRS, Doctor of Philosophy, HIV disease progression rates, R, Nausea, Lung, ADC, Daiichi Sankyo, Dor, TSE, Risk, Histology, ORR, ILD, Anemia, Platinum, Lung cancer, Weakness, Cancer, Patient, OS, Death, Toxicity, Neutropenia, UCLA Health, Medical imaging, Fine chemical, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery

Median PFS was 4.4 months in patients treated with datopotamab deruxtecan compared to 3.7 months with docetaxel.

Key Points: 
  • Median PFS was 4.4 months in patients treated with datopotamab deruxtecan compared to 3.7 months with docetaxel.
  • Results also showed a confirmed objective response rate (ORR) of 26.4% in patients treated with datopotamab deruxtecan compared to an ORR of 12.8% in patients treated with docetaxel.
  • Median PFS was 5.6 months in patients treated with datopotamab deruxtecan compared to 3.7 months in those treated with docetaxel.
  • At the March 29, 2023 data cut-off, 52 patients remained on treatment with datopotamab deruxtecan and 17 remained on docetaxel.

ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Retrieved on: 
Monday, October 23, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Principal, Neoplasm, Survival, AstraZeneca, Pneumonitis, Progression-free survival, IHC, American Society of Clinical Oncology, DOR, Thrombocytopenia, HER2, Immunohistochemistry, Congress, PFS, European Society for Medical Oncology, MD, Journal, Society, ADC, Disease, Medicine, TSE, Cancer, American Journal of Clinical Oncology, Annual general meeting, ILD, ORR, Anemia, Biliary tract, Overalls, University, Therapy, Patient, Neutropenia, ASCO, Fatigue, Pharmaceutical industry, Medical imaging, Daiichi Sankyo

Positive results from the ongoing DESTINY-PanTumor02 phase 2 trial showed that ENHERTU® (trastuzumab deruxtecan) continued to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple HER2 expressing advanced solid tumors.

Key Points: 
  • Positive results from the ongoing DESTINY-PanTumor02 phase 2 trial showed that ENHERTU® (trastuzumab deruxtecan) continued to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple HER2 expressing advanced solid tumors.
  • ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • Median follow-up was 12.75 months as of the data cut-off of June 8, 2023.
  • These clinically meaningful outcomes affirm the interim DESTINY-PanTumor02 results presented earlier this year at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial

Retrieved on: 
Sunday, October 22, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, DXD, Bevacizumab, Research, PRS, Ovarian cancer, Progression-free survival, Fatigue, CDH6, DOR, Vomiting, DCR, Diarrhea, PFS, Merck, HIV disease progression rates, Nausea, ADC, Disease, Daiichi Sankyo, Neoplasm, Sarah Cannon Research Institute, TSE, Recurrence, ILD, ORR, Anemia, Safety, European Society for Medical Oncology, Breast cancer, Patient, Appetite, PARP, Merck & Co., Medical imaging, Birth control, Pharmaceutical industry, MD

Updated results from a subgroup analysis of a first-in-human phase 1 trial showed that raludotatug deruxtecan (R-DXd) continues to demonstrate promising clinical activity in patients with heavily pretreated platinum-resistant advanced ovarian cancer.

Key Points: 
  • Updated results from a subgroup analysis of a first-in-human phase 1 trial showed that raludotatug deruxtecan (R-DXd) continues to demonstrate promising clinical activity in patients with heavily pretreated platinum-resistant advanced ovarian cancer.
  • These data were presented today during a mini-oral session ( 745MO ) at the 2023 European Society for Medical Oncology (#ESMO23).
  • “The response rate seen in these heavily pretreated patients is promising and further study of raludotatug deruxtecan in ovarian cancer is warranted.”
    The safety profile of raludotatug deruxtecan was consistent with previous reports from the phase 1 trial.
  • The median treatment duration was 18 weeks (range 3-115) and 33 patients remain on treatment with raludotatug deruxtecan.

Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

Retrieved on: 
Sunday, October 22, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Neoplasm, Appetite, DXD, PRS, PD-L1, Constipation, AstraZeneca, PD, Vomiting, Stomatitis, Congress, European Society for Medical Oncology, PFS, MD, CRS, HIV disease progression rates, TNBC, ADC, Dor, TSE, Breast cancer, ORR, ILD, Arm, Patient, Breast, Barts and The London School of Medicine and Dentistry, Fatigue, Medical imaging, Pharmaceutical industry, Daiichi Sankyo, Durvalumab

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Key Points: 
  • Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • “These results for datopotamab deruxtecan plus durvalumab in the first-line triple negative breast cancer setting are highly encouraging, particularly the 79% objective response rate,” said Peter Schmid, MD, Barts Cancer Institute, London, United Kingdom, and investigator in the trial.
  • “Disease progression after initial treatment is a reality for patients with triple negative breast cancer, underscoring the need for more durable treatment options,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development, Daiichi Sankyo.
  • As of the February 2, 2023 data cut-off, 29 patients (47%) remained on study treatment.

Renesas Announces New Organizational Structure to Accelerate Next Phase of Growth

Retrieved on: 
Thursday, October 19, 2023
Technology, Semiconductor, Internet of things, Signal, Enterprise Electronics Corporation, High performance organization, Sales, Digitalization, MCU, Organization, Acquisition, International Union of Operating Engineers, RA, Software, Senior, Intersil, Applied Materials, Growth, Quality assurance, Intel, TSE, Supercomputer, Head, Retirement, Synopsys, Renesas Electronics, Information technology, Global Sales Law Project, Marketing, Nitta, Nevada-California-Oregon Railway Co. General Office Building, Management, Engineering, Power, Analog

Renesas Electronics Corporation (TSE: 6723), a premier supplier of advanced semiconductor solutions, today announced a new organizational structure and leadership team appointments.

Key Points: 
  • Renesas Electronics Corporation (TSE: 6723), a premier supplier of advanced semiconductor solutions, today announced a new organizational structure and leadership team appointments.
  • Chris will be responsible for overseeing Renesas’ power management and discrete products and executing the company’s power strategies.
  • Renesas is creating a centralized engineering organization to solidify Renesas’ engineering foundation, from product to test engineering.
  • Hiroto Nitta, Roger Wendelken and Andrew Cowell will assist with the transition and leave Renesas by the end of the year.

Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs

Retrieved on: 
Friday, October 20, 2023
Research, FDA, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, MSD, TKI, DXD, NSCLC, SCLC, Cleavage, NYSE, ESMO, Food, Breakthrough therapy, Congress, MRK, European Society for Medical Oncology, Conference, GAAP, Regulation of tobacco by the U.S. Food and Drug Administration, HIV disease progression rates, Journal, Trastuzumab deruxtecan, ADC, Daiichi Sankyo, EPS, TSE, Spacecraft, American Journal of Clinical Oncology, Lung cancer, Cancer, Patient, BLA, Fine chemical, Pharmaceutical industry, Merck, Limited

The companies will jointly develop and potentially commercialize these ADC candidates worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights.

Key Points: 
  • The companies will jointly develop and potentially commercialize these ADC candidates worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights.
  • Merck also will pay Daiichi Sankyo up to an additional $5.5 billion for each DXd ADC contingent upon the achievement of certain sales milestones.
  • If Merck opts out of patritumab deruxtecan and/or raludotatug deruxtecan, the upfront payments already paid will be retained by Daiichi Sankyo and rights related to such DXd ADCs will be returned to Daiichi Sankyo.
  • The collaboration is expected to contribute to enhancing the corporate and shareholder value of Daiichi Sankyo over the medium to long term.